1기리쉬를 xbet Pharmaceutical Co., Ltd.

• Otsuka Pharmaceutical subsidiary Nutrition & Santé, engaged in the production and sale of functional foods and nutrition products, has acquired a business specializing in 1기리쉬를 xbet nutrition from the multinational dairy conglomerate, Lactalis.
• With 1기리쉬를 xbet recognition that more than 1% of Europeans suffer from celiac disease^*1, the market for 1기리쉬를 xbet products, made with soy, corn or rice flours, containing no wheat, is steadily growing.
• By acquiring a pioneer of gluten- and allergen-free nutrition, Nutrition & Santé obtains an integrated organization for the development, production and sale of 1기리쉬를 xbet products.

Tokyo, Japan -- Otsuka Pharmaceutical Co. Ltd. (Head office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) has announced the acquisition by subsidiary Nutrition & Santé (Head office: Revel, France; hereafter N&S) of the Valpiform company, formerly a member of the multinational dairy conglomerate, Lactalis Group. Valpiform is engaged in the production and sale of 1기리쉬를 xbet and allergy-free nutrition products. The acquisition was completed on December 28, 2012.

Established in 1990, Valpiform is a pioneer and French leader in 1기리쉬를 xbet and allergen-free nutrition. The company owns a state-of-the-art facility for manufacturing allergen-free food products. Approximately 40% of Valpiform sales are exported from France, with particularly strong markets in Italy and Benelux.
N&S has commissioned Valpiform for manufacturing of 1기리쉬를 xbet products since 2007, with sales in this category quadrupling　over the past five years. The acquisition of Valpiform gives N&S an integrated organization for the development, production and sale of 1기리쉬를 xbet products, creating a strong platform for timely expansion of the 1기리쉬를 xbet nutrition business.

In response to allergic reactions to gliadin, a gluten protein found in wheat and certain other cereal grains, 1기리쉬를 xbet foods are primarily produced using soy, corn or rice flour. In many European countries, celiac patients who suffer from this allergic reaction are able to obtain health insurance reimbursement for 1기리쉬를 xbet foods, and the market for 1기리쉬를 xbet products is growing steadily, year-on-year.

In reinforcing its position in 1기리쉬를 xbet products, N&S, operating in over 40 countries worldwide, including Europe, seeks to enhance its position as a leader of the health and functional nutrition business.

• *1：Celiac disease：Intolerance to gliadin (1기리쉬를 xbet protein) causes chronic inflammation of the lining of the small intestine. Typical symptoms include malabsorption, anemia, diarrhea, and bone-ache. Approximately 1% of the European population (approximately 5 million people) have been diagnosed with celiac disease. (www.idace.eu/1기리쉬를 xbet-foods)

Valpiform SAS

1기리쉬를 xbet & Santé SAS